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Summary
Background Deafness, onychodystrophy, osteodystrophy, mental retardation, and seizures (DOORS) syndrome is a 
rare autosomal recessive disorder of unknown cause. We aimed to identify the genetic basis of this syndrome by 
sequencing most coding exons in aﬀ ected individuals.
Methods Through a search of available case studies and communication with collaborators, we identiﬁ ed families that 
included at least one individual with at least three of the ﬁ ve main features of the DOORS syndrome: deafness, 
onychodystrophy, osteodystrophy, intellectual disability, and seizures. Participants were recruited from 26 centres in 
17 countries. Families described in this study were enrolled between Dec 1, 2010, and March 1, 2013. Collaborating 
physicians enrolling participants obtained clinical information and DNA samples from the aﬀ ected child and both 
parents if possible. We did whole-exome sequencing in aﬀ ected individuals as they were enrolled, until we identiﬁ ed a 
candidate gene, and Sanger sequencing to conﬁ rm mutations. We did expression studies in human ﬁ broblasts from 
one individual by real-time PCR and western blot analysis, and in mouse tissues by immunohistochemistry and real-
time PCR.
Findings 26 families were included in the study. We did exome sequencing in the ﬁ rst 17 enrolled families; we 
screened for TBC1D24 by Sanger sequencing in subsequent families. We identiﬁ ed TBC1D24 mutations in 
11 individuals from nine families (by exome sequencing in seven families, and Sanger sequencing in two families). 
18 families had individuals with all ﬁ ve main features of DOORS syndrome, and TBC1D24 mutations were identiﬁ ed 
in half of these families. The seizure types in individuals with TBC1D24 mutations included generalised tonic-clonic, 
complex partial, focal clonic, and infantile spasms. Of the 18 individuals with DOORS syndrome from 17 families 
without TBC1D24 mutations, eight did not have seizures and three did not have deafness. In expression studies, 
some mutations abrogated TBC1D24 mRNA stability. We also detected Tbc1d24 expression in mouse phalangeal 
chondrocytes and calvaria, which suggests a role of TBC1D24 in skeletogenesis.
Interpretation Our ﬁ ndings suggest that mutations in TBC1D24 seem to be an important cause of DOORS syndrome 
and can cause diverse phenotypes. Thus, individuals with DOORS syndrome without deafness and seizures but with 
the other features should still be screened for TBC1D24 mutations. More information is needed to understand the 
cellular roles of TBC1D24 and identify the genes responsible for DOORS phenotypes in individuals who do not have 
a mutation in TBC1D24.
Funding US National Institutes of Health, the CIHR (Canada), the NIHR (UK), the Wellcome Trust, the Henry Smith 
Charity, and Action Medical Research.
Introduction
Deafness, onychodystrophy, osteodystrophy, and mental 
retardation (DOOR or DOORS) syndrome (OMIM 
220500) is a rare autosomal recessive disorder of unknown 
cause. Ronald Cantwell ﬁ rst described DOOR syndrome 
in 1975,1 noting that a few similarly aﬀ ected individuals 
had been reported prior to that date. Qazi and colleagues 
suggested changing the name to DOORS syndrome to 
account for the presence of seizures in most 
individuals,2 and we use this term in this Article. The case 
reports of 32 aﬀ ected individuals were reviewed by James 
and colleagues in 2007,3 and ﬁ ve others have been 
published since that report.4–8 Seizures, present in most 
patients with DOORS syndrome, usually start in the ﬁ rst 
year of life. They occasionally occur with increasing 
frequency or severity and are sometimes refractory to 
antiepileptic drugs. The seizures are often generalised 
tonic-clonic, but myoclonic, partial, and absence seizures 
also occur.3 Neurological involvement—apart from the 
epilepsy, intellectual disability, and profound sensori-
neural hearing loss in most aﬀ ected individuals—includes 
occasional optic neuropathy, visual impairment, 
peripheral neuropathy, and abnormalities on brain MRI. 
The onycho-osteodystrophy aﬀ ects a patient’s hands and 
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feet equally. Small or absent nails and hypoplastic terminal 
phalanges are seen in most individuals. A triphalangeal 
thumb is present in a third of aﬀ ected individuals. A large 
base of the nose and a bulbous nose are the most common 
facial dysmorphisms. Cranial anomalies include 
microcephaly in a third of individuals and a narrow 
bifrontal diameter in two thirds. The rarity of DOORS 
syndrome, the absence of any single pathognomonic 
feature, the substantial clinical variability (including 
malformations of the brain, eyes, heart, kidneys, skeletal 
system, adrenal glands, and genitalia3), and features 
shared with other syndromes, make its clinical diagnosis 
challenging. In turn, such diﬃ  culties hinder 
understanding of its true prevalence and prognosis, 
limiting the possibility of accurate counselling. Better 
diagnostic measures are therefore needed.
For rare diseases in general, the identiﬁ cation of 
genetic causes has been a productive approach to 
improved understanding and more speciﬁ c diagnosis. 
The genetic cause of DOORS syndrome is un-
known.9 Strategies to identify disease-causing genes in 
inherited diseases have changed with the development 
and availability of new technologies. For example, in 
epilepsy, channelopathies were identiﬁ ed in the 1990s 
mostly with positional cloning and candidate gene 
sequencing.10 Next-generation sequencing, such as 
whole-exome sequencing, has accelerated the pace of the 
identiﬁ cation of epilepsy-associated genes. For instance, 
PPRT2 mutations were identiﬁ ed initially in paroxysmal 
kinesigenic dyskinesia, and are also seen in infantile 
seizures and febrile seizures.11,12 In the past year, 
DEPDC5 mutations have been identiﬁ ed in various 
dominantly-inherited familial focal epi lepsies.13,14 The 
precise role of each protein in the CNS has not been 
established. In a cohort of patients with a clinical 
diagnosis of DOORS syndrome, we sought to identify 
the genetic basis by whole-exome sequencing, aiming 
thus to provide improved diagnostic resolution and, 
eventually, a better understanding of the disorder.
Methods
Participants
We contacted previous collaborators and physicians who 
had published case reports of individuals with DOORS 
syndrome. Patients were from 26 centres in 17 countries. 
Between Dec 1, 2010, and March 1, 2013, we enrolled 
identiﬁ ed individuals with DOORS syndrome who were 
assessed by clinical geneticists and had at least three of 
the ﬁ ve following features: deafness, abnormal nails or 
digits on the hands or feet, developmental delay or 
intellectual disability (previously known as mental 
retardation), and seizures.
Families were excluded if the parents could not be 
contacted for consent or if DNA could not be obtained from 
the aﬀ ected individual. Further exclusion criteria were 
autosomal dominant inheritance and the absence of both 
intellectual disability and seizures, criteria that have been 
used elsewhere.3 A clinical questionnaire was completed by 
the collaborating physician. DNA was collected from the 
aﬀ ected individual and both parents if possible.
A parent provided written informed consent on behalf 
of the aﬀ ected individual. We did this study with the 
approval of the institutional ethics review boards of the 
Baylor College of Medicine (TX, USA), of University 
College London (London, UK), of the University of 
Amsterdam (Amsterdam, Netherlands), and of the 
University of Manchester (Manchester, UK). 
Procedures
A detailed description of the method for exome 
sequencing and data analysis is provided in the appendix. 
(p 2) Brieﬂ y, genomic DNA was fragmented, enriched for 
coding regions, and sequenced on an Illumina HiSeq 
2000 instrument (Illumina; San Diego, CA, USA). Reads 
were aligned to the reference human genome, and 
analysed for variations from the reference. The variants 
were ﬁ ltered to keep only rare or novel variants, and 
these variants were annotated for conservation data, 
predicted eﬀ ect of the variant, variant frequency in 
various databases such as the Exome Variant Server, gene 
expression pattern, function of the gene, and phenotypes 
in mice and human beings. Our variant detection and 
ﬁ ltering method was deliberately sensitive but not 
speciﬁ c, meaning that there are multiple false-positive 
variants identiﬁ ed. False-positive variant calls can be due 
to artifacts introduced by the next-generation technology 
used,15 poor coverage in GC-rich regions, bases missed 
by next-generation sequencing because of homopolymers 
or dinucleotide repeats, or mapping diﬃ  culties because 
of gene homologues or paralogues. The most eﬃ  cient 
method to remove these false-positive variants is to 
visualise alignment ﬁ les (binary alignment map ﬁ les), 
using Broad Institute’s IGV viewer from aﬀ ected 
individuals and compare them to variant ﬁ les from 
unaﬀ ected individuals or individuals with disorders 
unrelated to DOORS syndrome (exomes published 
elsewhere16–20), which we did after restricting the 
candidate gene list by focusing initially on genes with an 
autosomal recessive inheritance pattern (one 
homozygous mutation or two heterozygous mutations).
We did single nucleotide polymorphism (SNP) analysis 
with the Illumina Inﬁ nium HD assay platform using 
HumanOmni1-Quad BeadChip (Illumina) according to 
the manufacturer’s instructions, and analysed data using 
Illumina’s GenomeStudio to look for insertions, 
deletions, and regions of homozygosity as well as 
haplotypes shared by aﬀ ected siblings.
Primers used for Sanger sequencing of the genomic 
DNA that encodes the complete coding sequence of 
TBC1D24 variant 1 (NCBI CCDS ID#55980.1) were 
generated with an online software ExonPrimer (see 
appendix p 6 for a list of primers). We generated 
amplicons with 10 ng of genomic DNA using TaqMan 
polymerase (ABI, Life Technologies, Carlsbad, CA, USA) 
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with the manufacturer’s protocol with an annealing 
temperature of 55°C and an ampliﬁ cation of 1 min. 
Products were sequenced by the Sanger method using 
the same primers, at Beckman Coulter Genomics 
(Danvers, MA, USA). We analysed resulting chroma-
tograms by comparing the GenBank ﬁ le for the RefSeq 
sequence of TBC1D24 using Sequencher (version 4.8; 
Gene Codes Corporation, Ann Arbor, MI, USA).
We also did real-time PCR. We grew ﬁ broblasts in 
Dulbecco’s Modiﬁ ed Eagle’s Medium with 10% fetal 
bovine serum, 1·5 mM glutamine, 100 IU/mL penicillin, 
and 50 μg/mL streptomycin (Invitrogen, Grand Island, 
NY, USA). Mouse tissues were from C57BL/6J wildtype 
mice. RNA was extracted from ﬁ broblasts or mouse 
tissues using TRIzol and GlycoBlue, then cDNA was 
synthesised using SuperScript III First-Strand Synthesis 
Kit according to the manufacturer’s instructions (all 
from Invitrogen). We did quantitative real-time PCR 
using the primers listed in the appendix (p 6), the 
FastStart DNA Master SYBR Green reagent, and a 
LightCycler instrument using an annealing temperature 
of 65°C according to the manufacturer’s protocol (both 
from Roche NimbleGen, Madison, WI, USA).
Details of immunohistochemistry and western blotting 
methods used are in the appendix (pp 2–3). We generated 
the structural model of human TBC1D24 with Phyre2, an 
online software,21 based on the crystal structures of the 
TBC domain of TBC1D1 and TBC1D4 and the TBC, 
LysM, Domain catalytic (TLDc) domain of the zebraﬁ sh 
Oxr2 protein.22 We made the three-dimentional ﬁ gure 
using Pymol (version 1.6).
Statistical analyses
We calculated diﬀ erences in mRNA expression in 
ﬁ broblasts using the Student’s t test. For the expression 
in diﬀ erent mouse tissues, we did a Kruskal-Wallis one-
way ANOVA on ranks, as well as a multiple comparison 
procedure using Dunnett’s method. We used SigmaPlot 
(version 11.0) for all statistical analyses.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All authors had full access to all the 
data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
We identiﬁ ed 30 families, of which four were excluded 
from the study: two families that could not be re-contacted 
for informed consent; one family in which the aﬀ ected 
child had died and DNA was not available; and one family 
in which the phenotype corresponded to dominant 
deafness-ony chodystrophy (DDOD; OMIM 124480). We 
did exome sequencing in the ﬁ rst 17 enrolled families and 
SNP arrays in three of these families with consanguinity 
or more than one aﬀ ected child. Because sequencing and 
data preparation takes 3–5 months, we analysed exomes 
and SNP arrays after sequencing was completed in 
15 families (ﬁ gure 1). Of genes with rare or novel protein-
aﬀ ecting variants (compared with the frequency in the 
control group—ie, the 6503 exomes in the Exome Variant 
Server), 6645 genes had at least one rare or novel variant 
in at least one of ﬁ fteen samples. To restrict the list of 
candidate genes, we applied ﬁ ltering based initially on an 
autosomal recessive inheritance, analysed genes mutated 
in several samples, and removed the false-positive 
variants (appendix p 7). We visually compared the DOORS 
syndrome exome alignments to other exomes previously 
acquired for unrelated disorders,16–20 focusing initially on 
genes with a recessive inheritance pattern (one 
homozygous mutation or two heterozygous mutations) 
and variants identiﬁ ed in the highest number of aﬀ ected 
individuals. Most variants in genes identiﬁ ed in most 
exomes by our annotation pipeline proved to be false-
positive variants on visualisation and comparison with 
control exomes (appendix p 7).
We identiﬁ ed either homozygous or compound 
hetero zygous mutations in TBC1D24 (RefSeq# 
NM_001199107.1) in aﬀ ected individuals in six of the 
initial 15 families in which we did exome sequencing 
(table 1). All mutations were novel except for the 
frameshift mutation, seen in the heterozygous carrier 
state in two of 6118 individuals sequenced for that 
region in the June, 2013, release of the Exome Variant 
Server (EVS-v.0.0.20). This server provides variant 
frequency data for multiple exome studies done mostly 
in adults with various heart and lung diseases and 
controls, and individual phenotypes are not available. In 
view of the facts that mutations in this gene have been 
identiﬁ ed as the cause of some epilepsies,23–27 that 
seizures are common in people with DOORS syndrome, 
and that all mutations we identiﬁ ed were novel or very 
rare and in some cases truncating, this gene was the 
most suitable candidate in our cohort. We completed 
exome sequencing (followed by Sanger validation) in 
two individuals for whom exome sequencing was 
already started, and did Sanger sequencing of TBC1D24 
only in the nine subsequently enrolled families (see 
appendix p 6 for primers). We identiﬁ ed three more 
families with TBC1D24 mutations, one through 
additional exome sequencing and two by Sanger 
sequencing, totalling 11 aﬀ ected individuals from nine 
families with conﬁ rmed mutations in the cohort of 
26 families aﬀ ected by DOORS syndrome (see table 1 for 
the TBC1D24 mutations identiﬁ ed and the appendix p 4 
for analyses done on each family). Annotations for all 
TBC1D24 variants (from DOORS syndrome, the other 
associated epileptic disorders, and the Exome Variant 
Server), including population frequency, con servation 
scores and PolyPhen2 scores are in the appendix (p 8). 
Collectively, other coding variants in TBC1D24 were 
seen in the heterozygous state in 343 (5%) of 6503 of the 
Exome Variant Server cohort.
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We saw a wide variety of seizure types in our cohort of 
individuals with TBC1D24 mutations, including 
generalised tonic-clonic, complex partial, focal clonic 
seizures, and infantile spasms. Tables 2 and 3 list the 
clinical features of individuals with and without 
TBC1D24 mutations. Figure 2 shows photographs of the 
face, hands, feet, and radiographs. The mutations are 
listed in table 1 and shown in ﬁ gure 3. The conservation 
of the aﬀ ected residues and nucleotides is given in the 
appendix (p 17). In families with TBC1D24 mutations 
and con sanguinity, the mutations were homozygous and 
TBC1D24 was in a region of homozygosity as identiﬁ ed 
by SNP array or homozygosity mapping from exome 
data. The regions of homozygosity are given in the 
appendix (p 11).
Because of the recessive nature of the disease and the 
presence of mutations predicted to lead to premature 
protein termination, we proposed that the mutations 
cause a loss of TBC1D24 function. We assessed this 
hypothesis in ﬁ broblasts from a biopsy previously done 
for clinical reasons in individual 3, who was compound 
heterozygote for a splice site mutation and a frameshift 
mutation in trans. This frameshift mutation, because it is 
not in the last exon, is predicted to lead to nonsense-
mediated decay (NMD) of the mRNA.28 The splice donor 
mutation after exon ﬁ ve, because it is located ﬁ ve 
nucleotides away from a splice site (1206+5G→A), might 
or might not aﬀ ect splicing eﬃ  ciency. If it aﬀ ects splicing 
eﬃ  ciency, the mutation would lead to an aberrant 
protein-encoding mRNA, thus engaging NMD. To test 
for NMD, we did real-time PCR (ﬁ gure 3). 
TBC1D24 mRNA concentrations in the ﬁ broblasts from 
individual 3 were 5% (SE 1%) of the concentrations from 
three unaﬀ ected controls (Student’s t test p=0·024), 
conﬁ rming that the mRNA from both alleles undergoes 
NMD and thus showing a loss of TBC1D24 function. 
TBC1D24 protein from these ﬁ broblasts could not be 
detected by western blot analysis (ﬁ gure 3).
We next assessed Tbc1d24 tissue expression. Tbc1d24 is 
known to be widely expressed, most highly in the brain 
(especially in pyramidal neurons), kidneys, and salivary 
and lacrimal glands.29,30 In the brain, the regions with the 
highest expression levels are the hippocampus and the 
somatomotor areas of the isocortex (appendix p 13). Using 
an antibody against TBC1D24, we studied expression in 
digital chondrocytes, in view of the distal phalangeal 
hypoplasia in DOORS syndrome and the high expression 
seen in chondrocytes in the Human Protein Atlas. 
Expression was high in the chondrocytes of the distal 
phalanges of the forelimbs (appendix p 19). Moreover, we 
assessed expression by real-time PCR in various newborn 
mouse tissues and noticed high expression in the 
calvarium (appendix p 19), which correlates well with the 
cranial shape phenotype and occasional cranial synostosis 
seen in aﬀ ected individuals (table 2). 
TBC1D24 contains a TLDc domain and regulates Rab 
proteins. In our cohort, we identiﬁ ed no mutations in the 
other TLDc domain-containing genes by exome 
sequencing (appendix p 14). By homology modelling, the 
substitutions we identiﬁ ed did not seem to aﬀ ect portions 
of the protein predicted to interact with the TLDc domain, 
nor were they in the region that typically interacts with 
21 families with 3–5 main features of DOORS syndrome 
      assessed for eligibility
4 ineligible
    2 families could not be contacted for consent
    1 had DDOD syndrome
    1 had no sample available from aﬀected individual
17 families had exome sequencing in an 
      aﬀected individual (3 families with consanguinity or 
      aﬀected siblings also had SNP array)
Data analysis (done while 2 exomes pending):
TBC1D24 mutations identiﬁed in 6 families (7 after all 
exomes completed)
10 without 
      mutations
Sanger sequencing for TBC1D24 was done in 9 families
TBC1D24 mutations identiﬁed in 2 families  7 without    mutations
9 additional 
    eligible 
families 
    enrolled
17 families without TBC1D24 mutations (including 
9 with the 5 main features of DOORS syndrome). 
Analysis of the remaining exomes did not lead to 
the identiﬁcation of another gene mutated in 
most samples
9 families with TBC1D24 mutations 
7 with 
   mutations
Figure 1: Study proﬁ le
DOORS=deafness, onychodystrophy, osteodystrophy, mental retardation, and seizures. DDOD=dominant 
deafness-onychodystrophy.
Origin Maternal allele 
(DNA)
Maternal allele 
(protein)
Paternal allele 
(DNA)
Paternal allele 
(protein)
Individual 1 Japan 724C→T Arg242Cys 118C→T Arg40Cys
Individual 2a USA 724C→T Arg242Cys 724C→T Arg242Cys
Individual 2b USA 724C→T Arg242Cys 724C→T Arg242Cys
Individual 3 Germany 1008delT His336GlnfsTer12* 1206+5G→A Splicing
Individual 4 India 724C→T Arg242Cys 724C→T Arg242Cys
Individual 5a Chile 58C→G Gln20Glu 724C→T Arg242Cys
Individual 5b Chile 58C→G Gln20Glu 724C→T Arg242Cys
Individual 6 France 1008delT His336GlnfsTer12* Not identiﬁ ed Not identiﬁ ed
Individual 7 Brazil 724C→T Arg242Cys 724C→T Arg242Cys
Individual 8 Turkey 119G→T Arg40Leu 119G→T Arg40Leu
Individual 9 UK 328G→A Gly110Ser 999G→T Leu333Phe
Individuals with letters a and b after the number are siblings· *The histidine (His) at position 336 is replaced by a 
glutamine (Gln), which is followed by a frameshifted protein sequence (fs) ending with a termination codon (Ter) after 
12 aminoacids.
Table 1: Mutations identiﬁ ed in TBC1D24
For the Human Protein Atlas see 
http://www.proteinatlas.org/
ENSG00000162065
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GTP in other TBC proteins (ﬁ gure 3). Because 
TBC1D24 regulates Rab proteins and because of 
clinical overlap between DOORS syndrome and 
Martsolf syndrome, we also assessed RAB3GAP2. No 
RAB3GAP2 mutations were identiﬁ ed in families 
without TBC1D24 mutations (appendix p 14). Moreover, 
in genetic locus mapping by SNP arrays, or homozygosity 
mapping from exome data in some families without 
TBC1D24 mutations, we did not identify a mutated gene 
in common in these families (details on the regions 
identiﬁ ed are given in the appendix p 11). Analyses are 
ongoing to identify candidate genes with mutations in 
families following either a de novo dominant or a 
recessive inheritance pattern. Details on analysis in the 
ten exomes without TBC1D24 mutations are given in the 
appendix (pp 15–16).
Some individuals without TBC1D24 mutations had 
typical features of DOORS syndrome, including the more 
speciﬁ c signs of triphalangeal thumbs and 2-oxoglutaric 
aciduria, and were clinically in distinguishable from those 
BA DC FE
HG JI LK
NM O
QP SR UT
Figure 2: Physical features of participants with TBC1D24 mutations 
(A–F) Some individuals have a wide base of the nose and bulbous end of the nose (individual numbers from tables corresponding to each panel: A=3, B=6, C=5a, D=2b, E=2a, F=7). (G–L) Hands in 
individuals with TBC1D24 mutations have triphalangeal thumbs, brachydactyly, short terminal phalanges, and hypoplasia or aplasia of the nails (G=3, H=6, I=5a, J=2b, K=2a, I=7). (M–O) Feet with short 
terminal phalanges and hypoplasia or aplasia of the nails (M=3, N=6, O=5a). (P–S) Radiographs of the hands in individuals with TBC1D24 mutations. Note the triphalangeal thumbs and the short 
terminal phalanges (P=4, Q=5a, R=6, S=1). (T,U) Radiographs of the feet in individuals with TBC1D24 mutations, showing short terminal phalanges (T=6, U=5a).
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with TBC1D24 mutations. This ﬁ nding suggests genetic 
heterogeneity in DOORS syndrome. In the individuals 
without TBC1D24 mutations, eight did not have seizures 
and three did not have deafness (including one without 
seizures or deafness) and some individuals had additional 
malformations (eg, Arnold-Chiari malformation), which 
suggests that our cohort might include some individuals 
with disorders that overlap with but are diﬀ erent from 
DOORS syndrome (table 2). All individuals with 
TBC1D24 mutations had all ﬁ ve features making the 
DOORS acronym. If we stratify based on this strict 
deﬁ nition of DOORS syndrome, TBC1D24 mutations 
were seen in nine of 18 families.
Discussion
We have identiﬁ ed mutations in TBC1D24 as a probable 
cause of DOORS syndrome. Previously reported, but 
diﬀ erent, mutations in TBC1D24 cause various epileptic 
syndromes. A homozygous Phe251Leu substitution in 
four siblings of an Arab-Israeli family caused focal 
epilepsy, dysarthria, mild to moderate intellectual 
disability, and cortical thickening with cerebellar atrophy 
and a strong signal in the ansiform lobule of the 
cerebellum on T2-weighted and ﬂ uid-attenuated 
inversion recovery MRI.24 In an Italian family, compound 
heterozygous substitutions (Asp147His and Ala515Val) 
cause familial infantile myoclonic epilepsy (FIME 
[OMIM 605021]) in seven individuals with normal 
intellect and normal MRI, except for periventricular 
nodular heterotopia in one individual.25 A homozygous 
truncating mutation (969_970delGT, Ser324Thrfs*3) in 
exon 3 was identiﬁ ed in ﬁ ve Turkish individuals with a 
recessive form of myoclonic epilepsy with episodic 
dystonia, hemiparesis, autonomic signs, and 
lethargy.27 The ﬁ ve Turkish individuals developed the 
following: chronic dystonia, progressive diﬀ use cerebral 
atrophy, and early death. Exon 3 is spliced out in 
isoform 2, which is expressed predominantly in non-
neural tissues. Finally, two compound heterozygous 
substitutions (Phe229Ser and Cys156*) were identiﬁ ed in 
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Figure 3: Mutations in TBC1D24
(A) Location of the mutations identiﬁ ed in DOORS syndrome and in other epilepsy syndromes. Phe251Leu (blue; homozygous mutation, aﬀ ecting four 
siblings) causes focal epilepsy, dysarthria, intellectual disability, cortical thickening, cerebellar atrophy.23,24 Asp147His and Ala515Val (red; compound heterozygous 
mutation, aﬀ ecting seven individuals in one family) causes familial infantile myoclonic epilepsy.25 Ser324Thrfs*3 (purple; homozygous mutation, aﬀ ecting ﬁ ve 
individuals in one family) causes myoclonic epilepsy, dystonia, hemiparesis, autonomic signs, lethargy, progressive diﬀ use cerebral atrophy.27 Phe229Ser and Cys156* 
(green; compound heterozygous mutation aﬀ ecting two siblings)—causes familial malignant migrating partial seizures of infancy, progressive diﬀ use cerebral 
atrophy.26 The diagram also shows the exonic structure of TBC1D24, with the introns not drawn to scale. (B) Real-time PCR of TBC1D24 in ﬁ broblasts from the 
individual with a frameshift deletion and a splicing mutation, showing substantial reduction of TBC1D24 mRNA in aﬀ ected ﬁ broblasts. (C) Western blot analysis of 
the cells used in panel B, showing that TBC1D24 protein is undetectable by this method in aﬀ ected ﬁ broblasts. (D) Structural model of TBC1D24 with the TBC domain 
coloured in blue and the TBC, LysM, Domain catalytic (TLDc) domain coloured in grey. The N terminal and C termini are labelled, and the red spheres show the alpha 
carbon atoms of the residues aligning with the arginine and glutamine ﬁ ngers interacting with the GTP of Rab proteins in other TBC proteins,40 based on the structure 
of Gyp1p in complex with Rab33.37 The carbon atoms of residues substituted in DOORS syndrome are shown with purple spheres and those substituted in other 
epilepsy syndromes are shown with black spheres.
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two siblings with familial malignant migrating partial 
seizures of infancy, with progressive diﬀ use atrophy of 
the grey matter sparing the posterior fossa and early 
death.26 The diversity of seizure types seen in TBC1D24-
associated epileptic syndromes and in DOORS syndrome 
is striking (table 2), and might point to a general 
epileptogenic mechanism. None of the patients in 
previous reports of TBC1D24 mutations had digital 
anomalies or deafness, and none of the above mutations 
was identiﬁ ed in our DOORS syndrome cohort, showing 
a clear genotype-to-phenotype correlation. The reason 
why some mutations cause DOORS syndrome and 
others cause only epilepsy might lie partly in the way the 
mutations aﬀ ect interaction patterns with protein 
partners. This idea will need to be investigated. Some 
genes implicated in epilepsy seem capable of causing a 
wide variety of types of epilepsy, with greater or fewer 
additional neuro psychiatric features, and others have 
been associated with brain malformations or complex 
dysmorphic syn dromes.31 However, phenotypic 
pleiotropy has rarely been reported to span the spectrum 
from seizures alone (eg, previous reports on 
TBC1D24 mutations) to multi-systemic syndromic 
disorders such as DOORS syndrome. These emerging 
ﬁ ndings of both genotype-phenotype complexity and 
genetic pleiotropy lend support to the view that, with 
accumulating mutational data, the fuller coverage 
aﬀ orded by exome (or genome) sequencing might be 
more useful than targeted gene panels in clinical practice.
Five of the families with DOORS syndrome in our 
study have substitutions aﬀ ecting the arginine at 
position 242, and two have substitutions aﬀ ecting the 
arginine at position 40, suggesting that these residues 
are crucial in TBC1D24 function. Both are in a CpG 
island and aﬀ ect CG dinucleotides. CpG nucleotides are 
more mutation-prone, which might explain mutation 
recurrence in individuals of diﬀ erent ethnic origins. Two 
patients also shared another recurrent mutation unique 
to DOORS (His336Glnfs*12).
TBC1D24 is a member of the Tre2–Bub2–Cdc16 (TBC) 
domain-containing RAB-speciﬁ c GTPase-activating 
proteins, which coordinate Rab proteins and other 
GTPases for the proper transport of intracellular vesicles. 
TBC1D24 is the only TBC/RabGAP with a TLDc domain, 
which is thought to be involved in oxidative stress 
resistance and to have catalytic activity for unknown 
substrates.32,33 The TLDc domain is also seen in the 
proteins encoded by the human genes OXR1, NCOA7, 
KIAA1609, and C20orf118, which do not share known 
functions. Mice without Oxr1 have oxidative stress-
induced neuro degeneration,34 which suggests a possible 
link with the neurodegeneration seen in some individuals 
with TBC1D24 mutations.27 We saw no mutations in 
other TLDc domain encoding genes in this study. Several 
diseases have been associated with other aberrant Rab 
proteins and Rab-associated proteins. Some clinical 
overlap exists between DOORS syndrome and Martsolf 
syndrome (caused by mutations in RAB3GAP2 gene 
[OMIM 212720]; shared aspects include seizures, 
intellectual disability, abnormal toenails, and short 
phalanges), and other syndromes. We identiﬁ ed no 
mutations in RAB3GAP2.
Further research is needed to establish the precise 
role of TBC1D24 not only in the nervous system, but 
also in the skeletal system and other systems aﬀ ected in 
DOORS syndrome. In Caenorhabditis elegans, C31H2.1 
(a TBC1D24 orthologue) was implicated in synaptic 
function by an RNAi screen.35 In Drosophila, the 
orthologue Skywalker (Sky) enables endosomal 
traﬃ  cking in synaptic vesicles by facilitating GTP 
hydrolysis by Rab35, thus controlling synaptic vesicle 
rejuvenation and neurotransmitter release.36 Human 
TBC1D24 has low similarity to the Drosophila 
protein36 and neither possesses the arginine and 
glutamine residues (the so-called RQ ﬁ ngers) that are 
crucial to catalyse GTP hydrolysis by Rab 
proteins.37 Whether human TBC1D24 is able to also 
facilitate Rab protein-mediated GTP hydrolysis is not 
known.
Our ﬁ ndings implicate defective vesicular traﬃ  cking as 
the possible basis of the complex phenotype in 
individuals with DOORS syndrome in view of ﬁ ndings 
from previous studies in other TBC proteins (panel). The 
seizure phenotype present in all individuals with 
TBC1D24 mutations, and the studies in Drosophila, 
suggest a potential role for aberrant neurotransmitter 
Panel: Research in context
Systematic review
We searched PubMed and the references of included papers for articles published from Jan 1, 
1970, to March 1, 2013. We used the following search terms: “DOOR syndrome”, “DOORS 
syndrome”, “deafness and onychodystrophy”, “TBC1D24”, “2-oxoglutaric aciduria”, 
“2-oxoglutarate”, “epilepsy”, and “exome sequencing”. We retrieved all previous reports of 
individuals with DOORS syndrome and assessed the key clinical features, which present in 
most patients as sensorineural deafness, nail hypoplasia, terminal phalangeal hypoplasia, 
triphalangeal thumbs, developmental delay, intellectual disability, seizures, craniofacial 
anomalies, 2-oxoglutaric aciduria, and MRI anomalies. 25% or more of patients have 
consanguinity or aﬀ ected siblings, and optic atrophy. Fewer than 25% of patients have 
congenital heart defects, urinary tract anomalies, and peripheral neuropathy. Genetic testing 
in the one previous study excluded the candidate genes BMP4 and OGDH. 
Interpretation
Our ﬁ ndings suggest that mutations in TBC1D24 are a key genetic cause in some individuals 
with DOORS syndrome, and imply that testing for TBC1D24 mutations should be 
considered by clinicians if they suspect a diagnosis of DOORS syndrome. Our ﬁ ndings also 
substantiate the role of this gene in various epilepsy syndromes, as is seen also with other 
epilepsy-related genes such as SCN1A, KCNQ2, and PRRT2. Moreover, our ﬁ ndings lend 
support to the idea of pleiotropy in epilepsy genetics because, although some mutations in 
TBC1D24 can cause mild epilepsy without other substantial associated features, other 
mutations in TCB1C24 cause epilepsy as part of a syndrome with features beyond the 
nervous system. Our ﬁ ndings lend support to the idea that the genomic coverage provided 
by whole-exome sequencing is likely to prove useful in the diagnosis of rare neurological 
diseases that have clinical and genetic heterogeneity.
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release in the neurological manifestations of the disease. 
However, further studies in model organisms will be 
needed to study this in detail. At present, we are 
generating transgenic mice that will help us to assess 
these possibilities.
Exome sequencing, although a powerful method to 
identify new genes linked to mendelian disorders, does 
have limitations. In a medical genetics clinical setting, 
exome sequencing has a diagnostic yield of 
20–35%.38,39 Some limitations are linked to the strategy of 
sequencing only exons: promoter mutations or deep 
intronic mutations aﬀ ecting splicing will be missed. 
Other limitation are inherent to our study design; we did 
not analyse oligogenic inheritance (combination of one 
mutated allele in each of two or more genes) or 
synonymous exonic variants, which could be potentially 
deleterious. Finally, some limitations are technical—eg, 
GC-rich regions are diﬃ  cult to sequence and map, 
coverage can vary from sample to sample, and reads in 
genes that have paralogues or homologues can also be 
diﬃ  cult to map to the reference genome. Future 
strategies to identify the causative genes in individuals 
with DOORS syndrome but without TBC1D24 mutations 
could include consideration of oligogenic inheritance 
models, analysis of output for multiple diﬀ erent genes 
in the same pathway, an increase in enrolment and 
number of exomes or depth of exome sequencing, 
whole-genome sequencing, and analysis of exome data 
for copy-number variants.
The phenotypic similarity between patients with and 
without TBC1D24 mutations is highly suggestive of 
genetic heterogeneity in DOORS syndrome. In this 
study, individuals with TBC1D24 mutations all had the 
ﬁ ve features of the DOORS acronym. However, other 
features were greatly variable, in terms of seizure types, 
pharmacoresponsiveness, brain-imaging abnormalities, 
cranial shape, 2-oxoglutaric aciduria, a triphalangeal 
thumb, and growth parameters. We saw a similar pattern 
in individuals without TBC1D24 mutations: nine had the 
ﬁ ve features making the DOORS acronym; several had 
2-oxoglutaric aciduria or a triphalangeal thumb. Further 
discussion on 2-oxoglutaric aciduria is provided in the 
appendix (p 20).
Through a combination of careful clinical 
phenotyping and exome sequencing, we have identiﬁ ed 
the molecular basis of DOORS syndrome in about a 
third of individuals included in our cohort, or in half of 
the 18 families in which aﬀ ected individuals had the 
ﬁ ve features making the DOORS acronym. We suggest 
that individuals without deafness and seizures but with 
the other features should still be screened for 
TBC1D24 mutations because we are only beginning to 
understand the genetic causation of DOORS syndrome: 
the discovery of TBC1D24 mutations in a patient with 
an appropriate phenotype conﬁ rms the diagnosis of 
DOORS syndrome, but more cases need to be studied 
to establish the full clinical use of TBC1D24 mutation 
testing. As has occurred with other rare diseases for 
which genetic analysis has elucidated the cause, we 
hope that this gene discovery can help galvanise clinical 
and scientiﬁ c progress in understanding and treating 
DOORS syndrome.
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